FDA Review Back on Track – Corcept Resubmits Relacorilant for Cushing’s Treatment
Corcept will resubmit its NDA for relacorilant to treat Cushing’s syndrome after positive FDA feedback.
/ 352 items
#XY Event-Driven Stocks↓
American Cancer Society Adds Easy Shield Blood Test to Colon Cancer Screening Guidelines
New blood test added to cancer screening guidelines makes it easier to check for colorectal cancer, helping more people get tested early.
FDA Fast-Tracks First-Ever Treatment for Rare Muscle Disease LGMD2I/R9
BridgeBio’s BBP-418 receives FDA Priority Review with a November 27, 2026 PDUFA date. If approved, it would be the first therapy for LGMD2I/R9 and any form of limb-girdle muscular dystrophy.
Apogee Plunges in Premarket: Solid Eczema Drug Results, But Not Good Enough
Apogee stock fell after good but not great eczema drug results; strong data, but investors expected more.
Insulet Issues Voluntary Correction for Millions of Omnipod Pods
Insulet is recalling some insulin pods due to possible leaks causing low insulin delivery and health risks; replacements offered.
GeoVax Drops COVID Vaccine to Fast-Track Mpox and Cancer Programs
GeoVax stops COVID vaccine program to focus on mpox/smallpox and cancer drugs, aiming for faster approvals and growth.